Ozempic, Wegovy & Rybelsus Lawsuit Investigation
Submit a Gastroparesis and Stomach Injury Claim
Ozempic, Wegovy & Rybelsus Lawsuit Investigation
Our Ozempic lawsuit lawyers are investigating cases where individuals have suffered gastroparesis/stomach paralysis (“frozen stomach”) after using the weight loss drugs Ozempic, Wegovy, or Rybelsus because the manufacturer of these drugs failed to adequately warn patients and doctors of the risk of these dangerous gastrointestinal side effects.
How can I file a Ozempic/Wegovy/Rybelsus lawsuit claim?
You can trust Shamis & Gentile to handle your Ozempic/Wegovy/Rybelsus lawsuit for gastroparesis/stomach paralysis. If you or a loved one took a GLP-1 RA like Ozempic, Wegovy or Rybelsus and received a gastroparesis (stomach paralysis) or gastric obstruction, call us today for a free, no-obligation case evaluation. Call 305-479-2299 or complete a short Free Evaluation Form.
What Do We Know About Ozempic, Wegovy, and Rybelsus Gastroparesis/Stomach Paralysis Lawsuits?
Several lawsuits have been filed against the manufacturers of Ozempic, Wegovy, and Rybelsus, alleging that these medications can cause gastroparesis or stomach paralysis. These drugs, which are GLP-1 receptor agonists used for weight loss and diabetes management, have been associated with severe gastrointestinal issues in some patients.
Gastroparesis and Related Symptoms: Gastroparesis, or stomach paralysis, is a condition where the stomach muscles fail to function properly, causing delayed gastric emptying. Symptoms include severe nausea, vomiting, bloating, stomach pain, and a feeling of fullness after eating small amounts of food. The condition can lead to severe complications such as intestinal blockage, malnutrition, and dehydration.
Lawsuits and Allegations: Patients filing lawsuits claim that the manufacturers, Novo Nordisk (for Ozempic and Wegovy) and Eli Lilly (for Mounjaro), did not adequately warn about the risks of gastroparesis and other gastrointestinal side effects. These lawsuits allege that the drug makers downplayed these risks, leading to severe health issues for the users.
Eligibility for Lawsuits: To qualify for these lawsuits, patients typically need to demonstrate:
- Prescription of the drug for diabetes or weight management.
- Development of severe gastrointestinal issues, including gastroparesis, after starting the medication.
- Medical records linking their condition to the drug.
- Significant harm caused by these side effects, such as hospitalizations or missed work
Current Status and Legal Actions: The lawsuits are still in progress, with more patients potentially joining as awareness of the side effects increases. Some cases may be consolidated into multidistrict litigation (MDL) to streamline the legal process. Settlements might be reached outside of court to avoid prolonged litigation and additional negative publicity for the pharmaceutical companies.
How Much Compensation Can You Get in an Ozempic, Wegovy, or Rybelsus Settlement for Gastroparesis/Stomach Paralysis?
The compensation you could recover in a verdict or settlement in these semaglutide gastroparesis/stomach paralysis lawsuits depends on the type and extent of your injuries. Generally, a settlement in this type of case could cover several types of damages, including (but not limited to):
- Medical treatment costs (past and future), including surgery
- Medical expenses (past and future)
- Lost income (past and future)
- Pain and suffering related to injuries, treatment, and recovery (past and future)
- Loss of enjoyment of life (past and future)
- Loss of earning capacity
- Possible punitive damages
Our attorneys will fight to get you the maximum financial compensation to cover the losses you have suffered from gastroparesis/stomach paralysis after taking Ozempic, Wegovy, or Rybelsus diabetes weight loss drugs.
For those affected, you can trust Shamis & Gentile to handle your Ozempic/Wegovy/Rybelsus lawsuit for gastroparesis/stomach paralysis. If you or a loved one took a GLP-1 RA like Ozempic, Wegovy or Rybelsus and received a gastroparesis (stomach paralysis) or gastric obstruction, call us today for a free, no-obligation case evaluation. Call 305-479-2299 or complete a short Free Evaluation Form.
Really terrific law firm!!! I have worked with Shamis & Gentile on a number of cases, and have always felt connected to my attorneys no matter how many clients they may have. Excellent client services, great communication, and successful results! With Andrew Shamis’s representation, I have received thousands!
Daniel Getz
Shamis & Gentile Client
FAQs
News Updates for GLP-1 RA Ozempic, Wegovy, and Rybelsus Gastroparesis Lawsuits
May 2024
As of May 1, 2024, the Judicial Panel on Multidistrict Litigation (JPML) reports 87 cases are pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.
April 2024
On May 8, 2024, U.S. District Judge Gene E.K. Pratter issued Case Management Order No. 6, which expanded the Leadership Structure for the Ozempic lawsuits [IN RE: GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION (MDL 3094)]. \
March 2024
The first status conference for the Ozempic multidistrict litigation occurred last week, gathering attorneys from Novo Nordisk and plaintiffs who have either filed cases or are seeking positions in the plaintiffs’ attorney leadership group for the MDL. This initial case management meeting was conducted in a federal court in Pennsylvania.
February 2024
In February 2024, the Judicial Panel on Multidistrict Litigation (JPML) established MDL No. 3094, issuing a Transfer Order to centralize lawsuits claiming that the manufacturers of GLP-1 RA weight-loss drugs, such as Ozempic, Wegovy, and Rybelsus, did not adequately warn patients and doctors about the risk of severe gastrointestinal side effects.
Fifty-five ongoing actions and future related cases were moved to the Eastern District of Pennsylvania for consolidated pretrial proceedings, with the MDL assigned to the Honorable Gene E.K. Pratter.
The Timeline Important to the Ozempic, Wegovy, and Rybelsus Lawsuits
- 2012: Novo Nordisk researchers develop semaglutide as a diabetes therapy offering a longer-acting alternative to liraglutide.
- 2016: Clinical trials of Ozempic begin.
- 2016: The FDA New Drug Application is filed.
- 2017: Clinical trials of Ozempic are completed in May.
- 2017: Ozempic is approved by the United States Food and Drug Administration (FDA) in December as an injectable form of semaglutide to improve glycemic control in adults with type 2 diabetes mellitus.
- 2017: University of Leeds researchers and Novo Nordisk report that semaglutide can be used to treat obesity.
- 2018: Ozempic is approved in the European Union, Japan, and Canada.
- 2019: Novo Nordisk’s Rybelsus (a form of semaglutide taken by mouth) is approved for medical use in the U.S.
- 2020: Rybelsus is approved for medical use in the European Union.
- 2021: FDA approves Wegovy, Novo Nordisk’s semaglutide injection for long-term weight management in adults.
- 2021: More than 10,000 semaglutide-related adverse events are reported to the FDA Adverse Reporting System (FAERS).
- 2023: Ozempic and Wegovy are listed on FDA’s Durg Shortages list.
- 2023: Lawsuits are filed against Novo Nordisk on behalf of patients who took the drugs and developed gastroparesis/stomach paralysis problems
What Is the Treatment for Gastroparesis/Stomach Paralysis?
There is no cure for gastroparesis. Treatments for the condition appear to offer only temporary benefits, according to MedlinePlus, the authoritative source that gathers health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.
What are complications from Gastroparesis/Stomach Paralysis?
The National Institute of Diabetes and Digestive and Kidney Diseases lists a range of complications that can arise from gastroparesis:
- Dehydration from repeated vomiting
- Malnutrition stemming from poor nutrient absorption
- Difficulty controlling blood sugar (blood glucose) levels
- Low-calorie intake
- Decreased quality of life
- Bezoars (solid mass of food in the stomach, preventing digestion), which can cause:
- Blockage
- Ulcers
- Bleeding
- If a bezoar keeps food from moving to the small intestine, gastroparesis can be life-threatening.